BMO Capital Markets restated their hold rating on shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in a report issued on Friday, September 22nd. They currently have a $39.00 target price on the biotechnology company’s stock.
Other research analysts have also recently issued research reports about the stock. Jefferies Group LLC restated a buy rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. ValuEngine raised Five Prime Therapeutics from a strong sell rating to a sell rating in a research note on Friday, September 1st. BidaskClub lowered Five Prime Therapeutics from a sell rating to a strong sell rating in a research note on Wednesday, August 2nd. Finally, Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They set an outperform rating and a $41.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $54.86.
Five Prime Therapeutics (NASDAQ FPRX) traded up 4.82% during midday trading on Friday, hitting $40.91. 687,576 shares of the company traded hands. The stock’s 50-day moving average is $31.18 and its 200-day moving average is $32.04. Five Prime Therapeutics has a 12-month low of $25.97 and a 12-month high of $60.98. The firm’s market capitalization is $1.14 billion.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business had revenue of $7.80 million for the quarter, compared to the consensus estimate of $8.32 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The firm’s revenue was down 16.1% on a year-over-year basis. Analysts anticipate that Five Prime Therapeutics will post ($5.16) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/09/30/five-prime-therapeutics-inc-fprx-receives-hold-rating-from-bmo-capital-markets.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Laurion Capital Management LP purchased a new position in Five Prime Therapeutics in the 1st quarter worth approximately $210,000. Creative Planning raised its holdings in shares of Five Prime Therapeutics by 0.8% during the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares in the last quarter. Rockefeller Financial Services Inc. purchased a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth approximately $210,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Five Prime Therapeutics during the 1st quarter worth approximately $254,000. Finally, Tudor Investment Corp ET AL increased its position in shares of Five Prime Therapeutics by 56.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock valued at $290,000 after purchasing an additional 2,910 shares during the last quarter. 84.05% of the stock is currently owned by institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.